Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

ClinicalTrials.gov ID: NCT06868290

Public ClinicalTrials.gov record NCT06868290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Study identification

NCT ID: NCT06868290
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 126 participants

Conditions and interventions

Conditions

ANCA Associated Vasculitis (AAV)

Interventions

Biological · Other · Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 13, 2025 (Actual)
Primary completion: Jun 7, 2029 (Estimated)
Completion: May 24, 2030 (Estimated)
Last update posted: Sep 4, 2026

2025 – 2030

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
University Of Colorado	Aurora	Colorado	80045	—
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	—
Northwestern University	Chicago	Illinois	60611	—
Uni of Chi Medi Ctr Hema and Onco	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Michigan Med University of Michigan	Ann Arbor	Michigan	48109-5271	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Mayo Clinic Rochester	Rochester	Minnesota	55905	—
Duke Clinical Research Institute	Durham	North Carolina	27710	—
Oregon Health Sciences University	Portland	Oregon	97239	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Baylor University Medical Center	Dallas	Texas	75246	—
Houston Methodist Hospital	Houston	Texas	77030	—
LDS Hospital	Salt Lake City	Utah	84143	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06868290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 4, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06868290 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →